



Published in final edited form as:

J Hypertens. 2015 November ; 33(11): 2368–2370. doi:10.1097/HJH.0000000000000724.

A central role of H₄B deficiency in eNOS uncoupling in hypertension, Reply to “Creatine synthesis demands the majority of the bioavailable L-arginine”

Qiang Li, Ji-Youn Yon, and Hua Cai

Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA 90095, USA

We highly appreciate the quick response from Mr. Karamat [1]. His letter provides a novel research area in regard to the relationship between creatine kinase (CK) and nitric oxide (NO), and his group have given some evidences that CK system is associated with blood pressure [2, 3]. However, our review mainly focused on the role of H₄B deficiency in eNOS uncoupling in hypertension.

As we discussed in our review [4], H₄B deficiency plays a key role in determining eNOS uncoupling-dependent hypertension, which really exists and has been confirmed by many independent groups including us [5–9]. Therefore, the enzymes involved in H₄B biosynthesis, including de-novo synthetic pathway and salvage pathway, become significantly important for eNOS coupling states. In de novo synthetic pathway, H₄B is formed from guanosine-5'-triphosphate (GTP), through a sequence of enzymatic steps carried out by GTP cyclohydrolase I (GTPCHI), 6-pyruvoyl tetrahydropterin synthase (PTPS) and sepiapterin reductase (SPR) [10]. In the salvage pathway, the exogenous pterin precursor sepiapterin is firstly metabolized by SPR to H₂B, and further to H₄B by dihydrofolate reductase (DHFR) [11]. In hyperphenylalaninemia (hph)-1 mice, which display 90% deficiency of GTPCHI, the intracellular levels of H₄B as well as NO bioavailability are significantly lower in hph-1 mice than in WT mice [12]. In angiotensin II (Ang II)-infused mice, eNOS uncoupling contributes to high blood pressure, where aortic nitric oxide production was markedly decreased. The molecular mechanism involves a rapid and transient activation of endothelial NOX, subsequent H₂O₂-dependent down-regulation of DHFR, and persistent H₄B deficiency [13]. Therefore, DHFR overexpression or folic acid restoration of DHFR function effectively recoupled eNOS to reduce blood pressure [5, 14]. Furthermore, SPR was lost in the endothelium of DOCA-salt-induced hypertensive mice, and combined treatment of H₄B and a NOX inhibitor apocynin fully restored nitric oxide bioavailability. All these evidences emphasize the central role of H₄B for maintaining eNOS coupling in hypertension.

Address Correspondence to: Hua Cai, M.D., Ph.D., Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive Los Angeles, CA, 90095, Tel: 310-267-2303, Fax: 310-825-0132, hcail@mednet.ucla.edu.

Competing Interests

The authors have no conflicts of interest to report.

On the other hand, we can not deny the possible role of CK system in the development of hypertension. However, it is still unknown whether its effect on hypertension is through affecting NO production. Although creatine synthesis demands nearly 10 times the flux of plasma L-arginine represented by NO synthesis [1], the concentration of plasma L-arginine rarely falls below 60 mmol/l in pathological conditions, which is much higher than the amount need for eNOS ($K_m=3$ mmol/l). In this way, ADMA is considered as a much more influencing factor than CK. Moreover, there are evidences that multiple pathways for L-arginine uptake are present in vascular cells and L-arginine transport and NO formation are differentially controlled in these cells [15]. For example, the selective stimulation of L-arginine uptake in BAECs shows that L-arginine transport is dissociated from NO generation in these cells [15]. Therefore, the concentration of plasma L-arginine seems not that important. In addition, high levels of NO are known to stimulate apoptosis [16], which should be accurately controlled by the organism.

In conclusion, our review paper is mainly focused on a central role of H₄B deficiency in eNOS uncoupling in hypertension. Based on the major regulatory mechanisms, preserving eNOS coupling activity will be considered as a novel therapeutics for the treatment of hypertension.

Acknowledgments

This study was supported by National Institute of Health National Heart, Lung and Blood Institute (NHLBI) Grants HL077440 (HC), HL088975 (HC), HL108701 (HC, DGH), HL119968 (HC), an American Heart Association Established Investigator Award (EIA) 12EIA8990025 (HC), and an AHA Postdoctoral Fellowship Award 14POST20380966 (QL).

References

1. Karamat FA, van Montfrans GA, Brewster LM. Creatine synthesis demands the majority of the bioavailable L-arginine. *Journal of hypertension*. 2015 In press.
2. Karamat FA, Oudman I, Ris-Stalpers C, Afink GB, Keijsers R, Clark JF, et al. Resistance artery creatine kinase mRNA and blood pressure in humans. *Hypertension*. 2014; 63(1):68–73. [PubMed: 24126179]
3. Brewster LM, Mairuhu G, Bindraban NR, Koopmans RP, Clark JF, van Montfrans GA. Creatine kinase activity is associated with blood pressure. *Circulation*. 2006; 114(19):2034–9. [PubMed: 17075013]
4. Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. *Journal of hypertension*. 2015; 33(6):1128–36. [PubMed: 25882860]
5. Gao L, Chalupsky K, Stefani E, Cai H. Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. *Journal of molecular and cellular cardiology*. 2009; 47(6):752–60. [PubMed: 19660467]
6. Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. *The Journal of biological chemistry*. 2009; 284(41):28128–36. [PubMed: 19666465]
7. Sugiyama T, Levy BD, Michel T. Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. *The Journal of biological chemistry*. 2009; 284(19):12691–700. [PubMed: 19286667]

8. Gao L, Pung YF, Zhang J, Chen P, Wang T, Li M, et al. Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. *American journal of physiology Heart and circulatory physiology*. 2009; 297(1):H331–9. [PubMed: 19429835]
9. Du YH, Guan YY, Alp NJ, Channon KM, Chen AF. Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. *Circulation*. 2008; 117(8):1045–54. [PubMed: 18268143]
10. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. *Current drug metabolism*. 2002; 3(2):159–73. [PubMed: 12003348]
11. Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. *Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society*. 2011; 25(2):81–8. [PubMed: 21550412]
12. Cosentino F, Barker JE, Brand MP, Heales SJ, Werner ER, Tippins JR, et al. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. *Arteriosclerosis, thrombosis, and vascular biology*. 2001; 21(4):496–502.
13. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(25):9056–61. [PubMed: 15941833]
14. Gao L, Siu KL, Chalupsky K, Nguyen A, Chen P, Weintraub NL, et al. Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. *Hypertension*. 2012; 59(1):158–66. [PubMed: 22083158]
15. Durante W, Liao L, Iftikhar I, O'Brien WE, Schafer AI. Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. *Circulation research*. 1996; 78(6):1075–82. [PubMed: 8635238]
16. van't Hof RJ, Hocking L, Wright PK, Ralston SH. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. *Rheumatology*. 2000; 39(9):1004–8. [PubMed: 10986306]